Tesamorelin vs Hexarelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Hexarelin
Hexarelin is a potent synthetic hexapeptide growth hormone secretagogue. It provides the strongest GH release among GHRPs but is associated with rapid desensitization of receptors.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | Hexarelin |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Acts as a ghrelin mimetic with high potency at the GHS receptor. Provides powerful GH release but receptor desensitization occurs faster than with other GHRPs, requiring cycling. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Typical dosing: 100-200mcg administered 2-3 times daily for 4-6 weeks, followed by an equal off period to allow receptor resensitization. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Subcutaneous injection. Cycling is essential to maintain effectiveness. Often used in short bursts rather than continuous protocols. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Water retention, cortisol and prolactin increase, hunger (moderate), tingling, and potential blood pressure effects. |
| Best For |
What They Have in Common
Both Tesamorelin and Hexarelin are commonly used for: